A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Akeso
R-Pharm
Hoffmann-La Roche
National Cancer Institute (NCI)
Ningbo Medical Center Lihuili Hospital
Ipsen
Seagen Inc.
Sun Yat-sen University
Pfizer
Eli Lilly and Company
AstraZeneca
Merck Sharp & Dohme LLC
Pfizer
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Astellas Pharma Inc
Institut Cancerologie de l'Ouest
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AbbVie
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Canadian Cancer Trials Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Takeda
Providence Health & Services
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Sun Yat-sen University
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
AstraZeneca
National Cancer Center Hospital East
Baylor College of Medicine
Parabilis Medicines, Inc.
Taiho Oncology, Inc.
AstraZeneca
Genmab
NRG Oncology
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Seagen Inc.